Modified virus attacks tough ovarian cancer in new trial
Disease control
Recruiting now
This early-stage trial is testing whether a specially engineered virus called TILT-123, when combined with existing cancer drugs, is safe and potentially effective for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The virus is d…
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC